No Data
No Data
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersPulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that details of its upcoming Phase IIb clinical trial of nature-derived psilocybin in
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners With Fluence and INGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Psyence Biomed Partners With Fluence and INGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that its Australian subsidiary, Psyence Australia Pty Ltd. ("Psyence Australia"), has
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
No Data